diethylpropion hydrochloride

Trade name: tenuate

Small moleculeapproved

Approved

Aug 6, 1959

Diethylpropion is a sympathomimetic stimulant drug marketed as an appetite suppressant. Chemically, it is the N,N-diethyl analog of cathinone. Its mechanism of action is similar to other appetite suppressants such as sibutramine, phentermine and dextroamphetamine. Diethylpropion is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. Diethylpropion (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that diethylpropion can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. It is used in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. — NCATS

Clinical trial activity

1 trials · 2 clinical orgs · 13 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jul 1, 2005 (NCT00115063)

Timeline

1950s

Aug 6, 1959
Teva — Earliest FDA Approval
Aug 6, 1959
Teva — NDA Secondary Org
Aug 6, 1959
Nostrum Laboratories — Marketing Organization
Aug 6, 1959
Teva — NDA Organization
Aug 6, 1959
Nostrum Laboratories — NDA Secondary Org
Aug 6, 1959
MPP PHARMA — Marketing Organization
Aug 14, 1959
3M — NDA Secondary Org

1960s

Nov 17, 1960
Ani Pharmaceuticals — Marketing Organization

1970s

Mar 20, 1975
Sanofi-Aventis — NDA Secondary Org
Jul 19, 1979
Sandoz — Marketing Organization
Aug 15, 1979
Watson Pharmaceuticals — Marketing Organization

1980s

Aug 25, 1983
Chartwell Pharmaceuticals — Marketing Organization
Sep 20, 1984
Teva — Marketing Organization

2000s

Nov 5, 2008
Epic Pharma Llc — Marketing Organization

2010s

Dec 22, 2010
Avanthi Pharma — Marketing Organization
Jul 18, 2011
Lannett Company, Inc. — Marketing Organization

Indications

Approved for

Studied for

Obesity · Phase 4

Mechanism of action

Dopamine transporterINHIBITOR
SLC6A3 inhibitor
- Sodium-dependent dopamine transporter (SLC6A3) ↗
Norepinephrine transporterINHIBITOR
SLC6A2 inhibitor
- Sodium-dependent noradrenaline transporter (SLC6A2) ↗

Approval history

approvedPriority reviewAug 6, 1959

Chemistry & pharmacology

Loading structure…

SMILES

CCN(CC)C(C)C(=O)c1ccccc1

Mol. weight: 205.3 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Prescription Only

Oral

Yes

Parenteral

Topical

Sources

Also known as

1-phenyl-2-diethylamino-1-propanone
1-phenyl-2-diethylamino-1-propanone
2-(diethylamino)-1-phenyl-1-propanone
2-(diethylamino)-1-phenyl-1-propanone
2-(diethylamino)propiophenone
2-(diethylamino)propiophenone
adiposon
alpha-benzoyltriethylamine
alpha-benzoyltriethylamine
alpha-diethylaminopropiophenone
alpha-diethylaminopropiophenone
amfepramon
amfepramone
amfepramone
amfepramone
amfepramone
amfepramone hcl
amfepramone hydrochloride
amfepramonum
amfepramonum
amphepramon
amphepramone
anfepramona
anfepramona
apisate
diethpropion
diethylcathinone
diethylcathinone
diethylpropion
diethylpropion
diethylpropion
diethylpropion
diethylpropion
diethylpropion
diethylpropion
diethylpropion
diethylpropion
diethylpropion
(+-)-diethylpropion
(+-)-diethylpropion
(±)-diethylpropion
(±)-diethylpropion
diethylpropione
diethylpropion hcl
diethylpropion hcl
diethylpropion hcl
diethylpropion hydrochloride
diethylpropion hydrochloride
diethylpropion hydrochloride
diethylpropion hydrochloride
nopropiophenone
tenuate
tenuate
tenuate dospan
tenuate dospan
tepanil
tepanil
tepanil
tepanil ten-tab
tepanil ten-tab

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00115063	Phase 4	Jul 1, 2005	Louisiana Office of Group Benefits, University of Vermont

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Louisiana Office of Group Benefits	Academic/Hospital	1	0	1	2005
University of Vermont	Academic/Hospital	1	1	1	2005

2 organizations

Page 1 / 1

Marketing (16)

Organization	Org type	Relationship	Date
3M	For profit	NDA2	Aug 14, 1959
Ani Pharmaceuticals	For profit	MKTG	Nov 17, 1960
Avanthi Pharma	For profit	MKTG	Dec 22, 2010
Chartwell Pharmaceuticals	For profit	MKTG	Aug 25, 1983
Epic Pharma Llc	For profit	MKTG	Nov 5, 2008
Lannett Company, Inc.	For profit	MKTG	Jul 18, 2011
MPP PHARMA	For profit	MKTG	Aug 6, 1959
Nostrum Laboratories	For profit	MKTG	Aug 6, 1959
Nostrum Laboratories	For profit	NDA2	Aug 6, 1959
Sandoz	For profit	MKTG	Jul 19, 1979
Sanofi-Aventis	For profit	NDA2	Mar 20, 1975
Teva	For profit	NDA2	Aug 6, 1959
Teva	For profit	NDA	Aug 6, 1959
Teva	For profit	MKTG	Sep 20, 1984
UCB	For profit	MKTG	—
Watson Pharmaceuticals	For profit	MKTG	Aug 15, 1979